| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e9aee13868bfedebe2df1f13cda5490
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5c564991ae13d25b7772e76de8d0160e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-03 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-721
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4703
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-03 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 |
| filingDate |
2017-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_523eefa88a37861b59fe51c150e2990f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4bf236a748e6fa20b720c80d6b1211b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6936c1bd8c7b46f38faf98571de481aa |
| publicationDate |
2020-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10669310-B2 |
| titleOfInvention |
Peptide for cancer treatment and pharmaceutical composition containing same |
| abstract |
The present invention provides peptides containing a structure in which a portion of the dominant negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 is substituted with stapling structure(s). Peptides of the present invention have excellent cell growth inhibitory actions. Furthermore, their cell growth inhibitory actions continue for a longer time than the actions of peptides without stapling structures. Therefore, these peptides have features suitable for clinical applications in cancer therapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11091517-B2 |
| priorityDate |
2016-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |